Hepatitis B Virus (HBV) Capsid Inhibitors Market Set To Grow From $0.59 Billion In 2026 To $0.97 Billion By 2030 At A CAGR Of 13.4%
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Hepatitis B Virus (HBV) Capsid Inhibitors Market Revenue Growth Supported By A CAGR Of 0.97% Through 2030
The market for hepatitis B virus (HBV) capsid inhibitors has experienced rapid expansion in recent years. Projections indicate it will increase from $0.52 billion in 2025 to $0.59 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.7%. This historical growth has been driven by the worldwide prevalence of chronic hepatitis B infections, the shortcomings of current antiviral treatments, initial clinical successes with capsid inhibitors, enhanced financial support for virology research, and a surge in pharmaceutical pipeline developments.
In the coming years, the market for hepatitis B virus (HBV) capsid inhibitors is poised for notable expansion, with projections indicating it will reach a value of $0.98 billion by 2030, driven by a compound annual growth rate (CAGR) of 13.4%. The anticipated growth during this forecast period can be traced to several key drivers, including the broadening scope of combination therapies involving immunotherapies, increased financial commitments directed toward developing curative HBV treatments, a rising number of regulatory approvals granted for new antiviral agents, the expansion of global screening initiatives, and the progress being made with next-generation capsid inhibitors. Among the prominent trends shaping this period are a heightened emphasis on achieving functional cures for HBV infections, accelerated development of capsid assembly modulators, a growing adoption of combination therapy strategies, the broadening of late-stage clinical pipelines, and more refined efforts directed at disrupting viral replication mechanisms.
Download A Free Sample Report For Comprehensive Market Insights:
Hepatitis B Virus (HBV) Capsid Inhibitors Market Growth Factors Supporting Long-Term Expansion
The hepatitis B virus (HBV) capsid inhibitors market is anticipated to be driven forward by the rising incidence of hepatitis B infections. These infections, which affect the liver and are transmitted through exposure to infected blood or bodily fluids, can result in acute or chronic diseases, ultimately leading to severe outcomes such as liver cirrhosis or cancer. This growing prevalence is largely attributed to inadequate vaccination coverage, leaving many individuals vulnerable and facilitating the virus’s transmission via infected blood or bodily fluids. HBV capsid inhibitors work by interfering with the viral capsid’s formation and assembly, thereby halting viral replication and curbing the infection’s spread throughout the body. In April 2024, a report from the World Health Organization (WHO), an intergovernmental body based in Switzerland, indicated that by the end of 2022, merely 13% of chronic hepatitis B cases had been identified, with only about 3% (7 million people) undergoing antiviral therapy. For hepatitis C, 36% of those affected had been diagnosed, and 20% (12.5 million) received curative treatment—numbers that fall well short of the 2030 global objective to treat 80% of individuals with chronic hepatitis B and C. Consequently, the escalating prevalence of hepatitis B virus infections is fueling expansion in the HBV capsid inhibitors market.
Hepatitis B Virus (HBV) Capsid Inhibitors Market Segmentation And Category Breakdown
The hepatitis b virus (hbv) capsid inhibitors market covered in this report is segmented –
1) By Drug Type: Core Protein Allosteric Modulators (CpAMs), Capsid Assembly Modulators, Other Drug Types
2) By Application: Chronic Hepatitis B, Acute Hepatitis B, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By End-User: Hospitals, Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Core Protein Allosteric Modulators (CpAMs): Class I Core Protein Allosteric Modulators (CpAMs), Class II Core Protein Allosteric Modulators (CpAMs)
2) By Capsid Assembly Modulators: Direct Capsid Assembly Modulators, Indirect Capsid Assembly Modulators
3) By Other Drug Types: Novel Capsid Inhibitors, Combination Therapies, Experimental Mechanism-Based Inhibitors
Hepatitis B Virus (HBV) Capsid Inhibitors Market Industry Trends Shaping Future Revenue Growth
Key players in the hepatitis B virus (HBV) capsid inhibitors market are prioritizing innovations like oral small molecule capsid assembly modulators to boost antiviral effectiveness, improve patient adherence, and maintain long-term viral suppression. These oral small-molecule capsid assembly modulators are antiviral drugs taken by mouth that disrupt the formation of the HBV capsid, thereby halting viral replication and decreasing viral presence in the body. A notable example occurred in July 2024, when Aligos Therapeutics, Inc., a US-based clinical-stage biopharmaceutical firm, partnered with Xiamen Amoytop Biotech Co., Ltd., a Chinese biopharmaceutical company, to initiate a clinical trial assessing novel treatment options for chronic hepatitis B (CHB). This collaboration aims to utilize Aligos’s sophisticated capsid assembly modulator technology to improve antiviral outcomes and speed up the creation of next-generation HBV therapies. This initiative represents a major milestone in Aligos’s pursuit of developing effective, potentially curative solutions for individuals living with chronic hepatitis B.
Hepatitis B Virus (HBV) Capsid Inhibitors Market Competitive Analysis Of Major Industry Participants
Major companies operating in the hepatitis b virus (hbv) capsid inhibitors market are Johnson & Johnson, Roche Holding AG, GlaxoSmithKline plc, Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Novotech Health Holdings Pte. Ltd, Enanta Pharmaceuticals Inc., Assembly Biosciences Inc., Arbutus Biopharma Corporation, Aligos Therapeutics Inc., Qilu Pharmaceutical Co Ltd., Chia Tai Tianqing Pharmaceutical Group Co Ltd., Hepion Pharmaceuticals Inc., Shanghai Zhimeng Biopharma Inc., Antios Therapeutics, Bluejay Therapeutics Inc., Core Biopharma Inc., Door Pharmaceuticals, Shanghai Longwood Biopharmaceuticals Co. Ltd., Zhimeng Biopharma Inc.
Access The Complete Hepatitis B Virus (HBV) Capsid Inhibitors Market Report:
Hepatitis B Virus (HBV) Capsid Inhibitors Market Regional Analysis: Which Region Leads By Revenue?
Asia-Pacific was the largest region in the hepatitis B virus (HBV) capsid inhibitors market in 2025. The regions covered in the hepatitis b virus (hbv) capsid inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
